Trial · NCT00423319
Results by group322
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 322
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Rate of Composite of Adjudicated Venous Thromboembolic Event (VTE)-Related (Pulmonary Embolism and Symptomatic and Asymptomatic Deep Vein Thrombosis[DVT]) and All-cause Death During the Intended Treatment Period | Apixaban, 2.5 mg BID Plus Placebo | 1.39 | 95% Confidence Interval 0.95 to 2.02 | Percentage of events/patients evaluated | |
Rate of Composite of Adjudicated Venous Thromboembolic Event (VTE)-Related (Pulmonary Embolism and Symptomatic and Asymptomatic Deep Vein Thrombosis[DVT]) and All-cause Death During the Intended Treatment Period | Enoxaparin, 40 mg QD Plus Placebo | 3.86 | 95% Confidence Interval 3.08 to 4.83 | Percentage of events/patients evaluated | |
| Rate of Composite of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During Intended Treatment Period | Apixaban, 2.5 mg BID Plus Placebo | 0.45 | 95% Confidence Interval 0.24 to 0.85 | Percentage of events/patients evaluated | |
| Rate of Composite of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During Intended Treatment Period | Enoxaparin, 40 mg QD Plus Placebo | 1.14 | 95% Confidence Interval 0.77 to 1.69 | Percentage of events/patients evaluated | |
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Apixaban, 2.5 mg BID Plus Placebo | All-cause death | 0.11 | Percentage of events/patients evaluated | |
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Enoxaparin, 40 mg QD Plus Placebo | All-cause death | 0.04 | Percentage of events/patients evaluated | |
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Apixaban, 2.5 mg BID Plus Placebo | VTE-related death | 0.04 | Percentage of events/patients evaluated | |
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Enoxaparin, 40 mg QD Plus Placebo | VTE-related death | 0.00 | Percentage of events/patients evaluated | |
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Apixaban, 2.5 mg BID Plus Placebo | PE (fatal or nonfatal) | 0.11 | Percentage of events/patients evaluated | |
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Enoxaparin, 40 mg QD Plus Placebo | PE (fatal or nonfatal) | 0.19 | Percentage of events/patients evaluated | |
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Apixaban, 2.5 mg BID Plus Placebo | Nonfatal PE | 0.07 | Percentage of events/patients evaluated | |
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Enoxaparin, 40 mg QD Plus Placebo | Nonfatal PE | 0.19 | Percentage of events/patients evaluated | |
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Apixaban, 2.5 mg BID Plus Placebo | All DVT (n=1944, 1911) | 1.13 | Percentage of events/patients evaluated | |
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Enoxaparin, 40 mg QD Plus Placebo | All DVT (n=1944, 1911) | 3.56 | Percentage of events/patients evaluated | |
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Apixaban, 2.5 mg BID Plus Placebo | Symptomatic DVT | 0.04 | Percentage of events/patients evaluated | |
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Enoxaparin, 40 mg QD Plus Placebo | Symptomatic DVT | 0.19 | Percentage of events/patients evaluated | |
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Apixaban, 2.5 mg BID Plus Placebo | Asymptomatic DVT (n=1943, 1907) | 1.08 | Percentage of events/patients evaluated | |
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Enoxaparin, 40 mg QD Plus Placebo | Asymptomatic DVT (n=1943, 1907) | 3.30 | Percentage of events/patients evaluated | |
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Apixaban, 2.5 mg BID Plus Placebo | Proximal DVT (n=2196, 2190) | 0.32 | Percentage of events/patients evaluated | |
Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Enoxaparin, 40 mg QD Plus Placebo | Proximal DVT (n=2196, 2190) | 0.91 | Percentage of events/patients evaluated |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00423319/results